Skip to main content
Delfa

← All assets

LM11A-31

2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

2

Ongoing

2

Recruiting

0

Completed

0

Sites

0

Countries

0

Endpoints

20

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 20 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
2

Trials by status

Not yet recruiting
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Disease progression
8
Function / daily living
2
Neurodegeneration biomarkers
2
Neuroimaging
2
Caregiver / quality of life
2
Other clinical outcomes
2
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 2 of 20 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neurofilament light (NfL)Neurodeg.

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

2 of 2

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
PTPThe Progressive Supranuclear Palsy Clinical Trial Platform

AADvac1, LM11A-31

Frontotemporal dementia

MMSE ≥25Ph 2Not yet recruiting0Sep 2030-
NCT07264283The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

LM11A-31

Frontotemporal dementia

MMSE ≥25Ph 2Not yet recruiting0Sep 2030-

Showing 1-2 of 2 trials